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Abstract 5-Amino-4-imidazolecarboxamide riboside (AICAR)
is known to stimulate rat liver 5P-AMP-activated protein kinase
(AMPK). AMPK is the mammalian homologue of Snf1p in
yeast, involved in derepression of glucose-repressed genes. We
used AICAR to test if AMPK could also play a role in the
regulation of glucose-dependent genes in mammalian cells. At a
concentration which induces phosphorylation-dependent inactiva-
tion of HMG-CoA reductase, AICAR blocked glucose activation
of three glucose responsive genes, namely L-type pyruvate kinase
(L-PK), Spot 14 and fatty acid synthase genes in primary
cultured hepatocytes, but was without any action on glucose
phosphorylation to glucose 6-phosphate and on expression of
PEPCK, albumin and L-actin genes. AICAR was also found to
inhibit activation of the L-PK gene promoter by glucose in
transiently transfected hepatoma cells. Therefore our results
suggest that AMPK is probably involved in the glucose signal
pathway regulating gene expression in the liver.
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1. Introduction
The L-type pyruvate kinase gene (L-PK), encoding a key
glycolytic enzyme in the liver, is transcriptionally regulated,
positively by glucose and insulin and negatively by glucagon
and cAMP. Previous studies have demonstrated that this tran-
scriptional regulation by glucose and hormones could be as-
cribed to the glucose response element (GlRE) which contains
two E boxes located from 3168 to 3144 bp with respect to
the cap site [1^3]. Apart from the category of glucose-inde-
pendent insulin-stimulated genes represented by glucokinase
[4], most other insulin-sensitive genes investigated so far
seem to require the presence of glucose, for instance the genes
for aldolase B [5], phosphofructokinase-2 [6], fatty acid syn-
thase [7], Spot 14 [8], and L-PK [5]. The role of insulin in the
activation of these genes seems mainly to stimulate glucoki-
nase synthesis, and to permit glucose phosphorylation [9,10].
Glucose 6-phosphate (G 6-P) is thus the ¢rst step of glucose-
dependent activation of glucose-responsive genes in hepato-
cytes, and we have recently suggested that it could act through
the pentose phosphate pathway [11]. Although other investi-
gators proposed that G 6-P could be the active metabolite
[12], the role of pentose phosphate was recently supported
by in vivo studies [13]. In any case, whether the active metab-
olite is glucose 6-phosphate itself or a pentose phosphate, the
signaling pathway from this metabolite to the transcriptional
machinery remains unknown. In this paper we propose that
the 5P-AMP-activated protein kinase (AMPK) could be in-
volved in this pathway.
Mammalian AMPK is a multisubstrate protein kinase
which appears to play a central role in lipid metabolism
[14,15]. AMP was ¢rst identi¢ed to induce phosphorylation
and inactivation of HMG-CoA reductase and acetyl-CoA car-
boxylase, the rate limiting enzymes of cholesterol and fatty
acid synthesis, respectively. AMPK is activated by a high
AMP/ATP ratio inside the cell which occurs in stressed con-
ditions like heat shock, hypoxia, arsenite treatment and star-
vation [16]. In blocking anabolic pathways like cholesterol
and fatty acids synthesis, it preserves ATP for more vital
short-term functions like ion gradients across the plasma
membrane. The AMPK is the analogue of Snf1p in yeast
and shares with this protein 64% identity at the amino acid
sequence level in the catalytic region. The Snf1p protein kin-
ase is essential for derepression of glucose-repressed genes,
and permits fermentation of non-glucose sugars [17,18]. In
addition, Snf1p seems to be involved in the activation by
low levels of glucose of the glucose transporter HXT2 and
HXT4 genes, repressed in yeasts cultured in the presence of
a high glucose concentration [19]. This leads to the idea that
AMPK could also regulate the expression of glucose-regulated
genes in mammals. To test this hypothesis, we looked if acti-
vation of AMPK by 5-amino-4-imidazolecarboxamide ribo-
side (AICAR) in liver cells blocks the transcription of some
glucose-activated genes. Incubation of cells with AICAR
causes accumulation of ZMP, an AMP analogue [20] to
high level without disturbing the preexisting AMP, ADP
and ATP levels. It is actually the most speci¢c method to
activate AMPK in intact cells [21]. Our results suggest that
AMPK indeed controls the regulation of glucose-responsive
genes in mammals as well as in yeast.
2. Materials and methods
2.1. Plasmids
Plasmid constructions were done by standard cloning procedures
[22]. The constructs were veri¢ed by nucleotide sequencing. The di¡er-
ent plasmids constructed (termed 3183 PK/CAT, 3150 PK/CAT,
KSV2/CAT and (MLP)4 354 PK/CAT) have been previously de-
scribed [1,9,23].
2.2. Hepatocyte isolation and cell culture conditions
The mhAT3F hepatocyte-like cell line was derived from the tumoral
liver of transgenic mice expressing the SV40 large T and small T
antigens under the direction of the liver-speci¢c antithrombin III pro-
moter [9,24,25]. Cells were cultured in Ham’s F-12-Dulbecco’s modi-
¢ed Eagle’s medium (v/v) (Life Technologies, Inc.) supplemented with
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penicillin, streptomycin, 20 nM insulin, 1 WM triiodothyronine, 1 WM
dexamethasone, and 5% (v/v) fetal calf serum. Twenty-four hours
before the experiment, cells were cultured in a serum-free medium
containing 10 mM lactate and supplemented with the same mixture
of hormones as described above.
Hepatocytes were isolated from male Sprague-Dawley rats (180^
200 g) or from male B6/CBA mice (18^22 g) by the collagenase per-
fusion method [1]. Three millions of hepatocytes in suspension were
plated on 10-cm dishes in a ¢nal volume of 10 ml of 199 medium (Life
Technologies Inc.) supplemented with penicillin, streptomycin and
10% (v/v) fetal calf serum. After 12 h of attachment, the medium
was removed and replaced by a hormone-supplemented fresh 199
medium without glucose and with 10 mM lactate as a carbon source
for 24 h. Then the medium was changed for a fresh 199 medium with
di¡erent AICAR concentrations in the presence of glucose (25 mM)
or lactate (10 mM) for 24 h and total RNA was extracted for North-
ern blot analysis. For PEPCK mRNA study, 1 mM 8-bromoadeno-
sine 3P,5P-cyclic monophosphate (cAMP) was added in the lactate
medium.
2.3. Transfections and CAT assays
Transfection of the mhAT3F cell line was performed by lipofection
using N-(2,3-dioleoyloxy)propyl-N,N,N-trimethylammonium methyl-
sulfate (DOTAP, Boehringer Mannheim, Mannheim, Germany) ac-
cording to the manufacturer’s instructions. Five Wg of the tested con-
structs (3183 L-PK/CAT, 3150 L-PK/CAT or (MLP)4 354 L-PK/
CAT) or 3 Wg of the reference KSV2/CAT construct were transfected.
The medium containing the liposome-DNA complex was replaced
12 h later with fresh medium containing 10 mM lactate or 20 mM
glucose, and AICAR was added at di¡erent concentrations. Cells were
harvested 36 h after transfection and CAT activity assay was per-
formed as described [1]. The CAT activity was normalized with cel-
lular protein content and with respect to the KSV2/CAT activity as a
transfection standard.
2.4. Northern blot analysis
Total RNA was isolated from hepatocytes in primary culture by
lysis in guanidinium, followed by phenol extraction [26]. The RNA
concentration was determined spectrophotometrically. RNA samples
(15 Wg) were denatured at 65‡C for 15 min and electrophoretically
separated on 1% (w/v) agarose-formaldehyde gel, in 1U 3-(N-mor-
pholino)propanesulfonic acid (MOPS, Sigma, USA) bu¡er, trans-
ferred to nylon membrane (Hybond-N, Amersham), and ¢xed by
heating at 80‡C for 1 h. Prehybridization (4 h with 100 Wg/ml salmon
sperm DNA) and hybridization with L-PK [2], S14 [27], FAS [28],
PEPCK and rat serum albumin [24] cDNA probes were carried out as
described previously [2]. Each blot was stripped and reprobed with a
ribosomal 18S cDNA probe and quanti¢ed with PhosphorImager
(Molecular Dynamics).
2.5. HMG-CoA reductase assay
The HMG-CoA reductase assay was performed with digitonin-
permeabilized cells by the method of Geelen et al. [29], except that
the assay was performed on plated cells instead of cells in suspension.
The cells in culture dishes of 3.5 cm diameter were incubated with or
without di¡erent concentrations of AICAR for 30 or 60 min at 37‡C
and the culture medium was removed and replaced with 200 Wl of
assay mixture. The assay mixture contained the following compo-
nents: 16.7 mM imidazole (pH 7.2), 30 mM EDTA, 0.3 mM
EGTA, 50 mM KF, 33.5 mM glucose 6-phosphate, 3.4 mM NADP,
2.2 mM dithiothreitol, 0.33 mM 3-hydroxy-3-methyl-[3-14C]glutaryl-
CoA (2 dpm/pmol), 157.5 mU glucose 6-phosphate dehydrogenase
and 64 Wg of digitonin/mg cell protein. The reaction was stopped by
the addition of 20 Wl concentrated HCl at 8 min. Blanks were deter-
mined in all experiments by stopping the reaction at 0 min. The
mevalonate formed during the reaction was left to lactonize for at
least 30 min at 37‡C. As an internal standard [3H]mevalonolactone
was added to all samples. Cells were scraped, centrifuged and aliquots
of supernatant were chromatographed on silica gel thin layer plates
(Whatman K5D) in acetone/toluene (1:1, v/v), visualized with iodine
vapor, scraped into scintillation vials and counted for radioactivity.
2.6. Glucose 6-phosphate assay
Glucose 6-phosphate concentration was determined enzymatically
according to Slein [30] as described [10].
2.7. Protein assay
Protein concentration was determined according to Bradford [31] as
described [32].
2.8. Statistics
Results are given as means þ S.D. Statistical signi¢cance of di¡er-
ences between groups was determined by Student’s t-test for unpaired
data using the StatView software. The minimal level of signi¢cance
chosen was P6 0.05.
3. Results and discussion
3.1. AICAR inhibits glucose-dependent accumulation of L-PK,
Spot 14 and FAS mRNAs in hepatocytes in primary
culture but does not modify expression of genes which
are not stimulated by glucose
The group of Van den Berghe et al. [33], has reported that
FEBS 20508 20-7-98
Fig. 1. E¡ects of AICAR on the level of L-PK, S14, FAS and albu-
min mRNAs and on HMG-CoA reductase activity in cultured hepa-
tocytes. Mice hepatocytes (A) or rat hepatocytes (B) were cultured
either in 10 mM lactate or in 25 mM glucose. Northern blot was
performed with total RNA and hybridized with FAS, L-PK, S14
(A) and albumin (B) cDNA probes. C: PhosphorImager quanti¢ca-
tion of three independent Northern blot analyses of total RNAs
from rat hepatocytes hybridized with L-PK cDNA probe. The L-
PK RNA levels are expressed as mean þ S.D., and given in arbitrary
units. D: HMG-CoA reductase activity in rat hepatocytes in suspen-
sion incubated with glucose and increasing AICAR concentrations,
expressed as means þ S.D. in percentage of the activity in the ab-
sence of AICAR.
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incubation of isolated rat hepatocytes with AICAR provokes
inactivation of both acetyl-CoA carboxylase and HMG-CoA
reductase activities, and consequently inhibition of fatty acid
and cholesterol synthesis. These e¡ects result from the ability
of ZMP, the monophosphorylated metabolite of AICAR
which accumulates inside the hepatocytes, to stimulate liver
AMPK [34]. This stimulation can be explained by the struc-
tural analogy of ZMP with AMP [35]. A stimulatory e¡ect of
ZMP formed from AICAR on AMPK has also been reported
in adipocytes [21,36].
We compared the e¡ect of AICAR in hepatocytes in pri-
mary culture on the expression of genes stimulated (L-PK,
S14 and FAS) or not (albumin, PEPCK and L-actin) by glu-
cose. Fig. 1 shows that the glucose-dependent accumulation of
FAS, L-PK and S14 mRNAs was inhibited by AICAR while
the abundance of the glucose-independent albumin mRNA
was not. The same was true for PEPCK and L-actin mRNAs
whose levels were una¡ected by the presence of AICAR in the
medium; stimulation of the PEPCK gene by cAMP was nor-
mal in the presence of 300 WM AICAR (data not shown).
AICAR-dependent inhibition of glucose responsive genes be-
gan at 50 WM and was complete at 300 WM. In hepatocytes in
primary culture these AICAR concentrations also resulted in
the inhibition of HMG-CoA reductase activity, a well known
target of AMPK [37], indicating that AMPK is indeed acti-
vated in these cells. This result shows that the inhibitory e¡ect
of AICAR is speci¢c to glucose-responsive genes and is not
due to a non-speci¢c interference with energy production and
transcriptional machinery.
3.2. AICAR inhibits glucose-dependent activation of the L-PK
gene promoter in transiently transfected hepatoma cells
Fig. 2 shows that 500 and 700 WM of AICAR in the culture
medium of transfected mhAT3F cells inhibit induction of the
3183 L-PK/CAT construct by 20 mM glucose, in parallel
with an inhibition of the HMG-CoA reductase activity.
3.3. The AICAR inhibitory e¡ect requires the presence of a
functional glucose response element (GlRE)
Fig. 3A shows that the inhibitory e¡ect of AICAR requires
the presence of the GlRE. This inhibitory e¡ect is not ob-
served with the 3150 L-PK/CAT construct lacking the box
L4 that is to say the L-PK GlRE [1]. Instead, AICAR slightly
stimulated the 3150 L-PK promoter activity, as this is also
observed in the absence of glucose at 200 WM of AICAR with
the 3183 L-PK/CAT construct (Fig. 2). Since at this concen-
tration of AICAR the HMG-CoA reductase activity is not
reduced in mhAT3F cells, this unexpected stimulatory e¡ect
does not seem to involve activation of AMPK, and its mech-
anism is unknown. The complex assembled on the GlRE in-
cludes upstream stimulating factors (USF) 1 and 2 hetero-
dimers [1,23], which are essential components of this
complex [32,38,39]. To determine whether AMPK could act
directly on USF factors, we tested the e¡ect of AICAR on the
activity of the (MLP)4 354 L-PK/CAT plasmid in which 4
strong USF binding sites are oligomerized upstream of the
TATA box containing the proximal fragment of the L-PK
promoter [23]. Fig. 3B shows in fact that this construct was
stimulated rather than inhibited by AICAR, suggesting that
the AMPK acts through a functional GlRE, but not through
USF factors which are not glucose response elements [1].
3.4. The transcriptional inhibition of glucose responsive genes
by AICAR is not due to decreased glucose phosphorylation
into glucose 6-phosphate
The ¢rst step in the glucose signal pathway through tran-
scriptional machinery is the formation of G 6-P by glucoki-
nase or hexokinase [9,11]. G 6-P concentration in hepatocytes
was not a¡ected by AICAR (glucose 25 mM: 1.23 þ 0.65 and
glucose 25 mM+AICAR 300^500 WM: 0.93 þ 0.65 nmol/106
hepatocytes, P = NS). Consequently, blockade by AICAR of
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Fig. 3. E¡ects of AICAR on the activation of the 3150 L-PK/CAT
and the (MLP)4 354 L-PK/CAT constructs transfected in mhAT3F
hepatoma cells. Cells were cultured under the same conditions as in
Fig. 2. A: Transfection with the 3150 L-PK/CAT plasmid lacking
the GlRE. * Signi¢cantly lower than with the 3183 L-PK/CAT
constructs (P6 0.05). B: Transfection with the (MLP)4 354 L-PK/
CAT plasmid containing 4 strong binding sites for USF. * Signi¢-
cantly higher than AICAR 0 WM.
Fig. 2. E¡ect of AICAR on the glucose-dependent activation of the
3183 L-PK/CAT construct and on the HMG-CoA reductase activ-
ity in mhAT3F hepatoma cells. A: The mhAT3F cells were trans-
fected with the 3183 L-PK/CAT plasmid (containing the GlRE)
and incubated for 24 h in 20 mM glucose or 10 mM lactate with
various concentrations of AICAR. All values represent the
means þ S.D. of at least seven independent experiments. * Signi¢-
cantly higher than in lactate (P6 0.05). B: E¡ect of AICAR on
HMG-CoA reductase activity in permeabilized mhAT3F cells. Re-
sults were expressed relative to the activity of a control incubation
without AICAR in the presence of 20 mM glucose plus insulin
(20 nM). All values represent the means þ S.D. of at least seven in-
dependent experiments. * Signi¢cantly lower than control (P6 0.05).
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the response of glucose-activated genes to glucose was not a
secondary phenomenon due to decreased G 6-P accumulation
in cells cultured in high glucose medium. In addition, the
e¡ect of AICAR was detected in hepatocytes which synthesize
glucokinase, as well as in mhAT3F cells, which instead phos-
phorylate glucose through other hexokinase isoenzymes [9,40].
3.5. Does AMPK play a transcriptional role in mammals as
Snf1p does in yeasts?
The AMPK is considered as a fuel gauge in mammal cells,
being activated by a low ATP/AMP ratio which occurs in
stressed conditions. The activation of AMPK leads to inacti-
vation by phosphorylation of acetyl-CoA carboxylase, blocks
fatty acid synthesis, an energy consuming process, and, by
decreasing intracellular malonyl-CoA, permits activation of
carnitine palmitoyl-CoA transferase I and fatty acid oxidation
[41], thus restoring ATP stores. We suggest in this paper that
AMPK could also act at the transcriptional level to permit the
switch from a high carbohydrate diet to a low carbohydrate
diet or starvation by reducing the expression of glucose-de-
pendent genes in the liver. Glucose starvation in yeast leads to
activation of SnfIp and derepression of glucose repressed
genes required for metabolism of alternative carbon sources.
It is noteworthy to recall that we have previously suggested
that glucose could act on the transcriptional machinery
through pentose phosphates [11]. Xylulose 5-phosphate has
been reported to stimulate a protein phosphatase 2A-like en-
zyme [42,43]. We also found that okadaic acid, which specif-
ically inhibits protein phosphatases 1 and 2A, blocks the glu-
cose activation of the L-PK promoter in mhAT3F (B. Doiron,
unpublished data). Interestingly protein phosphatase 2A has
been shown to induce dephosphorylation of AMPK as well as
of Snf1p [44]. This is consistent with a dephosphorylation/
phosphorylation mechanism involved in the glucose signal
pathway through gene transcription.
Finally we think that the inhibitory e¡ect of AICAR does
not involve the cAMP inhibitory pathway because AICAR is
e¡ective in the mhAT3F cell line which has lost the cAMP
response for L-PK gene transcription inhibition [9].
In conclusion, the results presented here suggest that
AMPK might act at the transcriptional level to regulate spe-
ci¢cally glucose-responsive genes in mammals as Snf1p is in-
volved in the regulation of glucose-dependent genes in yeast.
More experiments will be needed to identify the putative part-
ners and targets of AMPK in the glucose signal pathway, and
to determine how it could manage to regulate glucose-respon-
sive genes, i.e. to tune the activity of the glucose response
complexes assembled on GlREs.
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